Evidence map›Paper›PMID 40309255›Full record

ArticleBioactive materials2025

Engineering fibroblast with reprogramming and spheronization for bone defect repair.

Yanjiao Li, Bin Jiang, Zhen Wu, Zhaoxia Ma, Lihua Qiu, Wen Cui, Yunhui Zhao, Jinghe Yan, Daiping Ma, Xingfei Wu and 5 more

Abstract read
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yanjiao LiYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Bin JiangR&D Division, Eureka Biotech Inc., Philadelphia, PA, United States.
Zhen WuShenzhen Zhendejici Pharmaceutical Research and Development Co., Ltd., Shenzhen, Guangdong, 518048, China.
Zhaoxia MaYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Lihua QiuYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Wen CuiYunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming, Yunnan, 650101, China.
Yunhui ZhaoYunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming, Yunnan, 650101, China.
Jinghe YanYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.
Daiping MaShenzhen Zhendejici Pharmaceutical Research and Development Co., Ltd., Shenzhen, Guangdong, 518048, China.
Xingfei WuYunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming, Yunnan, 650101, China.
Shu LiangYunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming, Yunnan, 650101, China.
Sitao WangYunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming, Yunnan, 650101, China.
Yanqun ZhaoYunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming, Yunnan, 650101, China.
Mengting WangShenzhen Zhendejici Pharmaceutical Research and Development Co., Ltd., Shenzhen, Guangdong, 518048, China.
Min HuYunnan Key Laboratory for Basic Research on Bone and Joint Diseases, Kunming University, Kunming, Yunnan, 650214, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone diseases profoundly affect patients, particularly the elderly, leading to severe health complications and disabilities. Osteoblasts play a crucial role in bone formation and are ideal candidates for treating bone diseases and engineering living materials. However, the stem and progenitor cells that give rise to osteoblasts, as well as osteoblasts themselves, exhibit dysfunction with aging. Although chemical reprogramming of fibroblasts into osteoblasts has been achieved, effective cell-based therapies or living materials have not been established in clinical practice. Here, we present a method to engineer fibroblasts through small molecule reprogramming and spheronization, achieving functional osteoblastic materials across all age groups. By primarily targeting the WNT signaling pathway and modularizing small molecules based on their effects on stage-specific genes, we optimized the temporal regulation of small molecules during reprogramming, acquiring a large number of healthy induced osteoblasts (iOBs). These iOBs with traits of functional native osteoblasts are ideal for forming transplantable tissue spheroids. As innovative living materials, the iOB spheroids (iOB-Sps) have demonstrated improved survival, significant self-bone formation, reduced ROS levels in the defect microenvironment, and accelerated endogenous osteogenesis and angiogenesis in vivo, promoting effective healing of bone defects. These material-free iOB-Sps function as self-scaffolding building blocks for biofunctional constructs, offering a promising avenue for clinical autologous bone defect repair, especially for the elderly.

Indexed as

Elderly autologous induced osteoblastEndogenous revascularization and osteogenesisEngineering fibroblastHigh productivity and survivalSpheroid

Identifiers

PMID40309255
PMCPMC12041790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.